Logan Coy Related postsA Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Elritercept (KER-050) for Transfusion-Dependent Anemia in Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (RENEW)September 11, 2026A First-In-Human Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Trial of VERT-002 in Locally Advanced or Metastatic Solid Tumors including NSCLC with MET AlterationsSeptember 11, 2026Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCLC (VIRO-25)September 11, 2026 Previous postA Phase 3 Randomized, Double-blind, Placebo-controlled Study of Bleximenib, Venetoclax and Azacitidine for Newly Diagnosed AML Harboring KMT2A Rearrangements or NPM1 Mutations Ineligible for Intensive ChemotherapyNext postA Phase 1/2 Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (ES-SCLC)